Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British ...
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback